Oncogenic mutations in the small guanosine triphosphatase RAS occur in 20% of human cancers, with RAS proteins activating both the mitogen-activated protein kinase (MAPK) and Phosphoinositide 3-kinase (PI3K) pathways (1–3). This evidence concerns the gene PIK3CA and cancer.